Longboard Pharmaceuticals Inc (LBPH)

$35.95

-0.05

(-0.14%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $35.54
    $37.21
    $35.95
    downward going graph

    1.14%

    Downside

    Day's Volatility :4.49%

    Upside

    3.39%

    downward going graph
  • $3.60
    $40.48
    $35.95
    downward going graph

    89.99%

    Downside

    52 Weeks Volatility :91.11%

    Upside

    11.19%

    downward going graph

Returns

PeriodLongboard Pharmaceuticals IncIndex (Russel 2000)
3 Months
92.55%
0.0%
6 Months
43.69%
0.0%
1 Year
393.14%
0.0%
3 Years
312.27%
-19.4%

Highlights

Market Capitalization
1.4B
Book Value
$8.07
Earnings Per Share (EPS)
-2.25
Wall Street Target Price
53.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.3%
Return On Equity TTM
-30.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-62.9M
Diluted Eps TTM
-2.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.8
EPS Estimate Next Year
-2.32
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Longboard Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 48.34%

Current $35.95
Target $53.33

Technicals Summary

Sell

Neutral

Buy

Longboard Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
78.5%
43.69%
393.14%
312.27%
115.92%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
NA
NA
NA
-1.8
-0.3
-0.19
NA
8.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
Buy
$1.4B
115.92%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Institutional Holdings

  • FMR Inc

    11.64%
  • Cormorant Asset Management, LLC

    8.62%
  • RA Capital Management, LLC

    8.46%
  • Farallon Capital Management, L.L.C.

    7.56%
  • T. Rowe Price Associates, Inc.

    5.70%
  • Wellington Management Company LLP

    5.49%

Company Information

longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.

Organization
Longboard Pharmaceuticals Inc
Employees
50
CEO
Mr. Kevin R. Lind
Industry
Miscellaneous

FAQs